150 results
8-K
EX-99.1
hxc9jb
6 Mar 24
Adaptimmune Reports Q4 /Full Year 2023 Financial Results and Business Updates
7:05am
8-K
EX-10.1
nip8bmam
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
S-8
EX-5.1
az50quiob
30 Nov 23
Registration of securities for employees
4:16pm
8-K
EX-99.1
trghloczv
8 Nov 23
Adaptimmune Reports Third Quarter Financial Results and Business Update
7:37am
8-K/A
EX-99.3
owga2wxg pxjwhei1u
10 Aug 23
Financial Statements and Exhibits
4:05pm
8-K
EX-99.1
yfu8rqbjcdm svm
9 Aug 23
Adaptimmune Reports Second Quarter Financial Results and Business Update
7:42am
8-K
EX-10.2
7xxv82dovam5ptc
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.1
4m25x
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.1
7xxtlwl g55pv
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
425
9297lqcw9y q73rhko
22 May 23
Business combination disclosure
7:01am
8-K
37xpe4xrxj
22 May 23
Other Events
6:59am